Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

To join this study, you must be an adult aged 18 or older. You need to have been diagnosed with pulmonary hypertension (high blood pressure in your lungs) that is linked to scarring in your lungs (interstitial lung disease, or ILD). This diagnosis must have been confirmed by special scans and heart tests within the last year.

You also need to be able to walk a certain distance – at least 100 meters but no more than 500 meters – in a six-minute walking test. If you are already taking medicines for your lung condition or other related illnesses, you should have been on a stable dose for at least one to three months before joining. Your doctor will carefully check all your medical records to make sure you meet these specific requirements.

There are also reasons why you might not be able to join. For example, if you have other types of pulmonary hypertension not related to ILD, or if you have certain heart problems or severe breathing conditions like COPD (chronic obstructive pulmonary disease). The study doctors will review your full health history to determine if this study is suitable for you.

If you decide to join this study, you will either receive the new inhaled medicine (TPIP) or a placebo (a dummy medicine) for 24 weeks. Neither you nor your study doctor will know which one you are taking. You'll need to take the study medicine once a day. Throughout the 24 weeks, you'll have regular visits to the clinic for medical checks, scans, and blood tests. You will also repeat the six-minute walking test several times to see how your exercise ability changes. After the main 24-week treatment period, there will be follow-up appointments to ensure your continued well-being. The total duration of your participation in the study, including follow-up, will be explained by the study team.